Evidence map›Paper›PMID 10885987›Full record

ReviewClinical microbiology reviews2000

Babesiosis.

M J Homer, I Aguilar-Delfin, S R Telford, P J Krause, D H Persing

Open access · greenAbstract readReview
In one paragraph

Review in Clinical microbiology reviews, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 352 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
352citing papers in PubMed, 3 pooled it
7.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

352 citing papers in PubMed, 3 syntheses or guidelines pooled it, 502 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. A Comprehensive Molecular Survey ofVeterinary sciences · 2026
    Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Molecular Detection of Tick-Borne Pathogens and Genetic Diversity ofAnimals : an open access journal from MDPI · 2026
    Article
  11. Molecular epidemiology and risk factors associated withJournal of parasitic diseases : official organ of the Indian Society for Parasitology · 2026
    Article
  12. Article
  13. Tafenoquine: A Breakthrough Option for Babesiosis Treatment.Tropical medicine and infectious disease · 2026
    Article
  14. Babesiosis and Its Significance in Transfusion Medicine from a European Point of View.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2026
    Review
  15. Photo Quiz: A camper with fever, headache, and fatigue.Journal of clinical microbiology · 2026
    Article
  16. Article
  17. Molecular epidemiology ofFrontiers in microbiology · 2026
    Article
  18. Immunity beyond borders: non-lethalFrontiers in immunology · 2026
    Article
  19. Article
  20. Article

292 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 5 institutions in 1 country.

M J HomerCorixa Corporation and The Infectious Disease Research Institute, Seattle, Washington 98104, USA.
I Aguilar-Delfin
S R Telford
P J Krause
D H Persing
Connecticut Children's Medical Center · USCorixa Corporation · USHarvard University · USInfectious Disease Research Institute · USMayo Clinic · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Babesiosis is an emerging, tick-transmitted, zoonotic disease caused by hematotropic parasites of the genus Babesia. Babesial parasites (and those of the closely related genus Theileria) are some of the most ubiquitous and widespread blood parasites in the world, second only to the trypanosomes, and consequently have considerable worldwide economic, medical, and veterinary impact. The parasites are intraerythrocytic and are commonly called piroplasms due to the pear-shaped forms found within infected red blood cells. The piroplasms are transmitted by ixodid ticks and are capable of infecting a wide variety of vertebrate hosts which are competent in maintaining the transmission cycle. Studies involving animal hosts other than humans have contributed significantly to our understanding of the disease process, including possible pathogenic mechanisms of the parasite and immunological responses of the host. To date, there are several species of Babesia that can infect humans, Babesia microti being the most prevalent. Infections with Babesia species generally follow regional distributions; cases in the United States are caused primarily by B. microti, whereas cases in Europe are usually caused by Babesia divergens. The spectrum of disease manifestation is broad, ranging from a silent infection to a fulminant, malaria-like disease, resulting in severe hemolysis and occasionally in death. Recent advances have resulted in the development of several diagnostic tests which have increased the level of sensitivity in detection, thereby facilitating diagnosis, expediting appropriate patient management, and resulting in a more accurate epidemiological description.

Indexed as

AnimalsBabesiaBabesiosisDisease SusceptibilityHumansPhylogenyProtozoan VaccinesVaccines, SyntheticProtozoan VaccinesVaccines, Synthetic

Identifiers

PMID10885987
PMCPMC88943
OpenAlexW4210974097

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.